and Thyroid Tumors

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2021 Aug 7

PMID 34359735

Citations 11

Authors

Georgia Pitsava

Constantine A Stratakis

Fabio R Faucz

Affiliations

Soon will be listed here.

Abstract

Thyroid cancer is the most common type of endocrine malignancy and the incidence is rapidly increasing. Follicular (FTC) and papillary thyroid (PTC) carcinomas comprise the well-differentiated subtype and they are the two most common thyroid carcinomas. Multiple molecular genetic and epigenetic alterations have been identified in various types of thyroid tumors over the years. Point mutations in , as well as and chromosomal rearrangements are common. Thyroid cancer, including both FTC and PTC, has been observed in patients with Carney Complex (CNC), a syndrome that is inherited in an autosomal dominant manner and predisposes to various tumors. CNC is caused by inactivating mutations in the tumor-suppressor gene encoding the cyclic AMP (cAMP)-dependent protein kinase A (PKA) type 1α regulatory subunit () mapped in chromosome 17 (17q22-24). Growth of the thyroid is driven by the TSH/cAMP/PKA signaling pathway and it has been shown in mouse models that PKA activation through genetic ablation of the regulatory subunit can cause FTC. In this review, we provide an overview of the molecular mechanisms contributing to thyroid tumorigenesis associated with inactivation of the gene.

Citing Articles

Expression of CLDN1 and EGFR in PTC.

Wu J, Wang Y, Yan L, Dong Y Discov Oncol. 2024; 15(1):562.

PMID: 39404969 PMC: 11480332. DOI: 10.1007/s12672-024-01428-9.

Possible link between familial susceptibility to cancer and the level of oxidative stress in thyroid cancer patients.

Javakhishvili I, Mardaleishvili K, Buleishvili M, Mantskava M, Chkhikvishvili I, Kalmakhelidze S Hered Cancer Clin Pract. 2024; 22(1):15.

PMID: 39180118 PMC: 11342469. DOI: 10.1186/s13053-024-00287-3.

The common pathogenesis of nodular goiter in both sexes: An exploration into gene expression and signaling pathways.

Gao X, Gao J, Sun Y, Zhao J, Geng L, Wang C Heliyon. 2024; 10(13):e33411.

PMID: 39035545 PMC: 11259846. DOI: 10.1016/j.heliyon.2024.e33411.

Identification of Key Genes and Imbalanced SNAREs Assembly in the Comorbidity of Polycystic Ovary Syndrome and Depression.

Cao Y, Wang W, Song X, Wen Q, Xie J, Zhang D Genes (Basel). 2024; 15(4).

PMID: 38674428 PMC: 11049873. DOI: 10.3390/genes15040494.

Dualistic Effects of PRKAR1A as a Potential Anticancer Target in Cancer Cells and Cancer-Derived Stem Cells.

Baek J, Nam A, Kim K, Kim P Int J Mol Sci. 2024; 25(5).

PMID: 38474121 PMC: 10932193. DOI: 10.3390/ijms25052876.

References

Bossis I, Stratakis C . Minireview: PRKAR1A: normal and abnormal functions. Endocrinology. 2004; 145(12):5452-8. DOI: 10.1210/en.2004-0900. View

Sugino K, Ito K, Nagahama M, Kitagawa W, Shibuya H, Ohkuwa K . Prognosis and prognostic factors for distant metastases and tumor mortality in follicular thyroid carcinoma. Thyroid. 2011; 21(7):751-7. DOI: 10.1089/thy.2010.0353. View

Kurihara T, Ikeda S, Ishizaki Y, Fujimori M, Tokumoto N, Hirata Y . Immunohistochemical and sequencing analyses of the Wnt signaling components in Japanese anaplastic thyroid cancers. Thyroid. 2005; 14(12):1020-9. DOI: 10.1089/thy.2004.14.1020. View

Brunton J, Steele S, Ziehr B, Moorman N, Kawula T . Feeding uninvited guests: mTOR and AMPK set the table for intracellular pathogens. PLoS Pathog. 2013; 9(10):e1003552. PMC: 3789714. DOI: 10.1371/journal.ppat.1003552. View

Aschebrook-Kilfoy B, Ward M, Sabra M, Devesa S . Thyroid cancer incidence patterns in the United States by histologic type, 1992-2006. Thyroid. 2010; 21(2):125-34. PMC: 3025182. DOI: 10.1089/thy.2010.0021. View

Charles R, Silva J, Iezza G, Phillips W, McMahon M . Activating BRAF and PIK3CA mutations cooperate to promote anaplastic thyroid carcinogenesis. Mol Cancer Res. 2014; 12(7):979-86. PMC: 4635659. DOI: 10.1158/1541-7786.MCR-14-0158-T. View

Tang L, Tong S, Zhan Z, Wang Q, Tian Y, Chen F . Expression of NUAK2 in gastric cancer tissue and its effects on the proliferation of gastric cancer cells. Exp Ther Med. 2017; 13(2):676-680. PMC: 5348656. DOI: 10.3892/etm.2016.3983. View

Cho-Chung Y, Nesterova M, Pepe S, Lee G, Noguchi K, Srivastava R . Antisense DNA-targeting protein kinase A-RIA subunit: a novel approach to cancer treatment. Front Biosci. 1999; 4:D898-907. DOI: 10.2741/cho-chung. View

Chevillard S, Ugolin N, Vielh P, Ory K, Levalois C, Elliott D . Gene expression profiling of differentiated thyroid neoplasms: diagnostic and clinical implications. Clin Cancer Res. 2004; 10(19):6586-97. DOI: 10.1158/1078-0432.CCR-04-0053. View

10.

Takahashi M, Li Y, Dillon T, Stork P . Phosphorylation of Rap1 by cAMP-dependent Protein Kinase (PKA) Creates a Binding Site for KSR to Sustain ERK Activation by cAMP. J Biol Chem. 2016; 292(4):1449-1461. PMC: 5270487. DOI: 10.1074/jbc.M116.768986. View

11.

Kari S, Vasko V, Priya S, Kirschner L . PKA Activates AMPK Through LKB1 Signaling in Follicular Thyroid Cancer. Front Endocrinol (Lausanne). 2019; 10:769. PMC: 6874117. DOI: 10.3389/fendo.2019.00769. View

12.

Nikiforova M, Kimura E, Gandhi M, Biddinger P, Knauf J, Basolo F . BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab. 2003; 88(11):5399-404. DOI: 10.1210/jc.2003-030838. View

13.

Esapa C, Johnson S, Kendall-Taylor P, Lennard T, Harris P . Prevalence of Ras mutations in thyroid neoplasia. Clin Endocrinol (Oxf). 1999; 50(4):529-35. DOI: 10.1046/j.1365-2265.1999.00704.x. View

14.

Almeida M, Muchow M, Boikos S, Bauer A, Griffin K, Tsang K . Mouse Prkar1a haploinsufficiency leads to an increase in tumors in the Trp53+/- or Rb1+/- backgrounds and chemically induced skin papillomas by dysregulation of the cell cycle and Wnt signaling. Hum Mol Genet. 2010; 19(8):1387-98. PMC: 2846157. DOI: 10.1093/hmg/ddq014. View

15.

Jenne D, Reimann H, Nezu J, FRIEDEL W, Loff S, Jeschke R . Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet. 1998; 18(1):38-43. DOI: 10.1038/ng0198-38. View

16.

Karga H, Lee J, VICKERY JR A, Thor A, Gaz R, Jameson J . Ras oncogene mutations in benign and malignant thyroid neoplasms. J Clin Endocrinol Metab. 1991; 73(4):832-6. DOI: 10.1210/jcem-73-4-832. View

17.

Hattori M, Minato N . Rap1 GTPase: functions, regulation, and malignancy. J Biochem. 2003; 134(4):479-84. DOI: 10.1093/jb/mvg180. View

18.

Carroll B . Asymptomatic thyroid nodules: incidental sonographic detection. AJR Am J Roentgenol. 1982; 138(3):499-501. DOI: 10.2214/ajr.138.3.499. View

19.

Baloch Z, LiVolsi V . Special types of thyroid carcinoma. Histopathology. 2017; 72(1):40-52. DOI: 10.1111/his.13348. View

20.

Pringle D, Yin Z, Lee A, Manchanda P, Yu L, Parlow A . Thyroid-specific ablation of the Carney complex gene, PRKAR1A, results in hyperthyroidism and follicular thyroid cancer. Endocr Relat Cancer. 2012; 19(3):435-46. PMC: 3667702. DOI: 10.1530/ERC-11-0306. View